ELK1-YBX1 signaling promotes cisplatin resistance via ferroptosis adaptation in bladder cancer
Cellular Signalling · 2026-10 · 146 · 112633
DOI: 10.1016/j.cellsig.2026.112633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026-10. Verfasst von Yao Luo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Ce…. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Signal Transduction, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Lanzhou University, Natural Science Foundation of Gansu Province, Science and Technology Program of Gansu Province.
Abstract (Originalsprache)
Bladder cancer (BC) is one of the most common malignancies of the urinary system, and chemoresistance remains a major obstacle limiting the clinical efficacy of cisplatin-based chemotherapy. Elucidating the mechanisms underlying cisplatin resistance may facilitate the identification of potential therapeutic targets and ultimately improve patient outcomes. In this study, we found that Y-box binding protein 1 (YBX1) was upregulated in bladder cancer tissues with poor chemotherapeutic response as well as in cisplatin-resistant bladder cancer cell lines, where it promoted tumor cell proliferation and invasion. Functional assays demonstrated that depletion of YBX1 significantly enhanced cisplatin sensitivity in both in vitro and in vivo. Mechanistically, elevated YBX1 expression was associated with reduced ferroptosis sensitivity in cisplatin-resistant cells. Although YBX1 induced autophagy and was accompanied by a reduction in glutathione peroxidase 4 (GPX4) protein levels, the overall enhancement of intracellular antioxidant capacity in resistant cells may partially offset the increased susceptibility to ferroptosis caused by GPX4 degradation. Furthermore, we identified the transcription factor ELK1 as an upstream regulator that transcriptionally upregulates YBX1, while YBX1 may contribute to the cisplatin-resistant phenotype through activation of the p62-NRF2-associated antioxidant pathway. Collectively, these findings highlight a critical role of YBX1 in cisplatin resistance and suggest that targeting YBX1 may represent a promising strategy for overcoming cisplatin-based chemoresistance in bladder cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou, University, Lanzhou 730000, Gansu Province, China; Lanz…
- Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou, University, Lanzhou 730000, Gansu Province, China.
- Department of Urology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China.
- Department of Urology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital; School of Medicine, Fuzhou University. No.134, Dong Street, Fuzhou 350001, People's Republic of China.
- Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou 730000, Gansu Province, China; Department of Urology, Gansu Province Clinical Research Center for Urinary System Disease,The Second Hospita…
- Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou, University, Lanzhou 730000, Gansu Province, China. Elec…
Förderung
- Lanzhou University
- Natural Science Foundation of Gansu Province
- Science and Technology Program of Gansu Province
Zitieren
APA
Luo, Y., Ma, J., Wang, C., Xiong, W., Zhang, X., Zhang, B., Fu, Y., Zhang, X., Wang, J., Zhang, H., Zheng, Y., Lu, J., & Shang, P. (2026). ELK1-YBX1 signaling promotes cisplatin resistance via ferroptosis adaptation in bladder cancer. Cellular Signalling, 146, 112633. https://doi.org/10.1016/j.cellsig.2026.112633
Vancouver
Luo Y, Ma J, Wang C, Xiong W, Zhang X, Zhang B, et al. ELK1-YBX1 signaling promotes cisplatin resistance via ferroptosis adaptation in bladder cancer. Cellular Signalling. 2026;146:112633. doi:10.1016/j.cellsig.2026.112633
BibTeX
@article{Luo2026,
author = {Luo, Yao and Ma, Junhai and Wang, Cheng and Xiong, Wei and Zhang, Xingxing and Zhang, Biao and Fu, Yuqiang and Zhang, Xiaojun and Wang, Jieneng and Zhang, Helin and Zheng, Yanghuang and Lu, Jianzhong and Shang, Panfeng},
title = {ELK1-YBX1 signaling promotes cisplatin resistance via ferroptosis adaptation in bladder cancer},
journal = {Cellular Signalling},
year = {2026},
volume = {146},
pages = {112633},
doi = {10.1016/j.cellsig.2026.112633}
}
EUVIMED